PRRX1 and neoplasm: Compared with the primary tumour in the group of injecting subcutaneously PRRX1 overexpressed SACC‐83 cells, the concentration and category of FFAs in the metastatic tumour with PRRX1 overexpressed SACC‐83 cells via the tail vein were significantly increased.